Exscientia and Sanofi establish strategic research collaboration to ...
WEBJan 7, 2006 · Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples.
Exscientia Announces Expansion of its Current Collaboration with Sanofi …
WEBDec 21, 2023 · OXFORD, England-- (BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration.
Sanofi signs drug development partnership with Exscientia worth …
WEBJan 7, 2022 · Sanofi, the Paris-based pharmaceutical giant, has signed a research collaboration with Exscientia, which uses artificial intelligence to discover new drug candidates, that could be worth up to...
Sanofi partners with AI firm Exscientia to develop up to 15 new …
WEBJan 7, 2022 · French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone...
Another big AI deal as Sanofi taps Exscientia for 15 new drugs
WEB1 day ago · Shortly after Amgen unveiled its $1.9 billion alliance with Generate Biomedicines aimed initially at five drug molecules, Sanofi has announced a big expansion of its longstanding partnership with...
Exscientia Announces Expansion of its Current Collaboration with Sanofi …
WEBOXFORD, England, December 21, 2023 -- (BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by...
Exscientia and Sanofi establish strategic research collaboration to ...
WEBJan 7, 2022 · Exscientia and Sanofi will collaborate to identify and select target projects, leveraging Exscientia’s personalised medicine platform. The platform enables a “patient-first” approach through...
Exscientia - Exscientia announces multi-target, AI-driven drug ...
WEBMay 19, 2021 · Exscientia’s AI centric, end-to-end drug discovery platform is set to revolutionise the process invention of new drugs, designing therapeutics for areas of high unmet medical need that could positively impact patients, with timelines that are many years shorter than industry standards.
Sanofi partners with AI firm Exscientia to develop up to 15
WEBJan 7, 2022 · French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone...
Sanofi Forms Potential $5.2 Billion AI Deal With Exscientia
WEBJan 7, 2022 · Sanofi formed a deal to develop 15 experimental oncology and immunology drugs with Exscientia Plc with possible total payouts of as much as $5.2 billion, allying with a company that uses ...
Skip to content